Depomed Inc  

(Public, NASDAQ:DEPO)   Watch this stock  
Find more results for Grunenthal GMBH�
+0.55 (2.94%)
After Hours: 19.25 0.00 (0.00%)
Jul 28, 4:55PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.74 - 19.37
52 week 12.25 - 33.11
Open 18.74
Vol / Avg. 807,809.00/1.11M
Mkt cap 1.15B
P/E     -
Div/yield     -
EPS -1.41
Shares 61.10M
Beta 1.22
Inst. own 113%
Aug 19, 2016
Depomed Inc Extraordinary Shareholders Meeting Add to calendar
Aug 3, 2016
Q2 2016 Depomed Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 3, 2016
Q2 2016 Depomed Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 12, 2016
Depomed Inc at Cantor Fitzgerald Healthcare Conference - Webcast
Jun 21, 2016
Depomed Inc at JMP Securities Life Sciences Conference - Webcast
May 23, 2016
Depomed Inc at UBS Global Healthcare Conference
May 18, 2016
Depomed Inc Annual Shareholders Meeting
May 11, 2016
Depomed Inc Annual Shareholders Meeting (Estimated)
May 10, 2016
Depomed Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 5, 2016
Q1 2016 Depomed Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -19.96% -22.10%
Operating margin -4.12% -14.71%
EBITD margin - 17.61%
Return on average assets -6.23% -7.32%
Return on average equity -27.29% -22.29%
Employees 494 -
CDP Score - -


7999 Gateway Blvd Ste 300
NEWARK, CA 94560-1188
United States - Map
+1-510-7448000 (Phone)
+1-510-7448001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.

Officers and directors

Peter D. Staple Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
James A. Schoeneck President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
August J. Moretti Chief Financial Officer, Senior Vice President
Age: 64
Bio & Compensation  - Reuters
Matthew M. Gosling Senior Vice President, General Counsel
Age: 44
Bio & Compensation  - Reuters
Srinivas G. Rao M.D. Ph.D. Chief Medical Officer and Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Richard Scott Shively Senior Vice President, Chief Commercial Officer
Age: 58
Bio & Compensation  - Reuters
Thadd M. Vargas Senior Vice President - Business Development
Age: 49
Bio & Compensation  - Reuters
Karen A. Dawes Independent Director
Age: 63
Bio & Compensation  - Reuters
Louis J. Lavigne Jr. Independent Director
Age: 68
Bio & Compensation  - Reuters
Samuel R. Saks M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters